The reverse merger and large PIPE validate Mentari's pipeline and provide ample capital. Monitor shareholder vote (INM requires 2/3 approval) and Nasdaq listing approval. The stock price may reflect the upcoming change in value but carries execution risk until closing.
Price Chart
Executive Summary
InMed Pharmaceuticals (INM) entered into a definitive agreement to acquire Mentari Therapeutics via reverse merger, with Mentari shareholders receiving a majority stake in the combined entity. A concurrent PIPE of at least $150 million will fund operations and support the merged company's pipeline. The transaction includes a contingent value right for pre-merger INM shareholders and represents a transformative change of control.
Key Financial Metrics
Key Facts
- Reverse merger: INM acquires Mentari Therapeutics through merger subsidiaries; Mentari shareholders become majority owners of combined entity.
- Mentari valued at $125 million (base Company Equity Value), subject to upward adjustment from PIPE proceeds.
- Concurrent PIPE of at least $150 million from institutional investors, committed via securities purchase agreement.
- Pre-merger INM shareholders receive one CVR per share, entitling them to future contingent payments.
- Combined company to be renamed Mentari Therapeutics, Inc. and will continue trading on Nasdaq.
- New directors and officers from Mentari will take control at closing.
Financial Impact
Mentari base valuation $125M; PIPE adds ≥$150M; combined entity post-money valuation substantially higher than INM's current ~$2M market cap.
Risk Factors
- Failure to obtain required shareholder approval (two-thirds of INM shares).
- Nasdaq listing not granted for combined company.
- PIPE investors may not fund if conditions are not met; termination fee of $4M payable by Mentari if PIPE fails.
- Delays beyond December 31, 2026 end date could terminate deal.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-058795 |
| Document: ea029148201ex10-5.htm | 0001213900-26-058795 |
| Document: ea029148201ex10-4.htm | 0001213900-26-058795 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 22d ago | 425 | $1.31 $1.39 | ▲ +6.11% | ▲ +6.61% | $1.34 (+2.29%) |
Jul 10, 2026 11w ago | 8-K | $1.57 $1.52 | ▲ +3.18% | ▲ +2.40% | $1.34 (+14.65%) |
Jul 2, 2026 13w ago | S-4 | $1.56 $1.66 | ▼ −6.41% | ▼ −5.48% | $1.34 (+14.10%) |
Jun 11, 2026 16w ago | Insider Cluster | $1.58 $1.49 | ▼ −5.70% | ▼ −6.13% | $1.34 (−15.19%) |
Jun 10, 2026 16w ago | 8-K | $1.51 $1.48 | ▼ −1.99% | ▼ −5.42% | $1.34 (−11.26%) |
May 19, 2026 19w ago | 425 | $1.60 $1.69 | ▲ +5.63% | ▲ +3.38% | $1.34 (−16.25%) |
May 19, 2026 19w ago | 8-K | $1.60 $1.69 | ▲ +5.63% | ▲ +3.38% | $1.34 (−16.25%) |
May 19, 2026 19w ago | 8-K | $1.60 $1.66 | ▼ −3.75% | ▼ −1.45% | $1.34 (+16.25%) |
Apr 27, 2026 22w ago | 8-K | $0.7010 $0.7480 | ▼ −6.70% | ▼ −5.01% | $1.34 (−91.16%) |
Apr 3, 2026 25w ago | 8-K | $0.6950 $0.7130 | ▲ +2.59% | ▼ −1.54% | $1.34 (+92.81%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access